Co-founded on April 14th, 2016 by Jérôme Parcq and Christophe Gaudin, Op2Lysis is a startup in Biotechnology, which develops the first medical treatment of hemorrhagic stroke, the most severe form of stroke.
Currently at preclinical stage of development for its product, O2L-001, Op2Lysis has raised its visibility in the field of iotechnology and gained many rewards over 2017. Labeled by Medicen, stamped “young innovative company” by the French Ministry of Research and Technology, rewarded with the special jury prize at Biovision, then winner of the Netva and i-LAB competitions, Op2lysis has been selected at the Big Booster Camp in 2018. Op2Lysis values more than ten years of a research program initially conducted at Inserm in Caen.
Op2Lysis is pursuing its adventure with a team of 4, with complementary skills. Op2Lysis is based in Paris area and in Normandy, with its Headquarter in Boulogne-Billancourt and R&D facilities in Caen, at Cyceron center.
Op2Lysis originated from a meeting between Christophe Gaudin et Jérôme Parcq in 2014, initiated by Denis Vivien, Director of the Inserm Unit U1237. Both had an entrepreneurial ambition and complementary skills in neurosciences and cardiovascular product development. They decided to create a company dedicated to development of Jérôme’s invention, O2L-001. This leads to create Op2Lysis on April 14th 2016, in order to acquire the exclusive license of the product, then to set up the development plan and initiate fundraising to perform this development.
« Our ambition is to be a leader in research and development for stroke management »